Format

Send to

Choose Destination
Cell. 2010 Aug 20;142(4):511-2. doi: 10.1016/j.cell.2010.08.004.

Reversing cachexia.

Author information

1
Nutritional Biomedicine, School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK. m.j.tisdale@aston.ac.uk

Abstract

Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

PMID:
20723750
DOI:
10.1016/j.cell.2010.08.004
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center